Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025)

Spyre Therapeutics' Tax Provisions history spans 5 years, with the latest figure at -$15000.0 for Q1 2025.

  • For Q1 2025, Tax Provisions fell 146.88% year-over-year to -$15000.0; the TTM value through Dec 2025 reached -$15000.0, down 129.41%, while the annual FY2025 figure was -$15000.0, 129.41% down from the prior year.
  • Tax Provisions reached -$15000.0 in Q1 2025 per SYRE's latest filing, down from $1000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $92000.0 in Q2 2021 to a low of -$209000.0 in Q3 2022.
  • Average Tax Provisions over 5 years is -$846.15, with a median of $9000.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: tumbled 903.85% in 2022, then skyrocketed 500.0% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $23000.0 in 2021, then surged by 65.22% to $38000.0 in 2022, then tumbled by 92.11% to $3000.0 in 2023, then crashed by 66.67% to $1000.0 in 2024, then crashed by 1600.0% to -$15000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Tax Provisions are -$15000.0 (Q1 2025), $1000.0 (Q4 2024), and $18000.0 (Q3 2024).